Instem plc provides information technology solutions to the life science market worldwide.
Flawless balance sheet with proven track record.
Share Price & News
How has Instem's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: INS has not had significant price volatility in the past 3 months.
7 Day Return
GB Healthcare Services
1 Year Return
GB Healthcare Services
Return vs Industry: INS exceeded the UK Healthcare Services industry which returned -19.7% over the past year.
Return vs Market: INS exceeded the UK Market which returned -23.6% over the past year.
Price Volatility Vs. Market
How volatile is Instem's share price compared to the market and industry in the last 5 years?
Simply Wall St News
2 weeks ago | Simply Wall StIs Instem plc's (LON:INS) CEO Pay Fair?
1 month ago | Simply Wall StRead This Before Buying Instem plc (LON:INS) Shares
1 month ago | Simply Wall StIs Instem's (LON:INS) 190% Share Price Increase Well Justified?
Is Instem undervalued compared to its fair value and its price relative to the market?
Undervalued compared to fair value
Share Price vs. Fair Value
Below Fair Value: INS (£4.44) is trading below our estimate of fair value (£4.54)
Significantly Below Fair Value: INS is trading below fair value, but not by a significant amount.
Price To Earnings Ratio
PE vs Industry: INS is poor value based on its PE Ratio (40.5x) compared to the Healthcare Services industry average (39.4x).
PE vs Market: INS is poor value based on its PE Ratio (40.5x) compared to the UK market (12.6x).
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate INS's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: INS is overvalued based on its PB Ratio (4.2x) compared to the GB Healthcare Services industry average (2.4x).
How is Instem forecast to perform in the next 1 to 3 years based on estimates from 2 analysts?
Forecasted annual revenue growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: Insufficient data to determine if INS's forecast earnings growth is above the savings rate (0.5%).
Earnings vs Market: Insufficient data to determine if INS's earnings are forecast to grow faster than the UK market
High Growth Earnings: Insufficient data to determine if earnings are expected to grow significantly over the next 3 years.
Revenue vs Market: INS's revenue (11.4% per year) is forecast to grow faster than the UK market (2.5% per year).
High Growth Revenue: INS's revenue (11.4% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: INS's Return on Equity is forecast to be low in 3 years time (14.9%).
How has Instem performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: INS has high quality earnings.
Growing Profit Margin: INS's current net profit margins (7.4%) are higher than last year (6.5%).
Past Earnings Growth Analysis
Earnings Trend: INS's earnings have grown significantly by 44.7% per year over the past 5 years.
Accelerating Growth: INS's earnings growth over the past year (27.3%) is below its 5-year average (44.7% per year).
Earnings vs Industry: INS earnings growth over the past year (27.3%) exceeded the Healthcare Services industry -3.8%.
Return on Equity
High ROE: INS's Return on Equity (10.4%) is considered low.
How is Instem's financial position?
Financial Position Analysis
Short Term Liabilities: INS's short term assets (£13.8M) exceed its short term liabilities (£12.8M).
Long Term Liabilities: INS's short term assets (£13.8M) exceed its long term liabilities (£4.8M).
Debt to Equity History and Analysis
Debt Level: INS is debt free.
Reducing Debt: INS has no debt compared to 5 years ago when its debt to equity ratio was 4.3%.
Debt Coverage: INS has no debt, therefore it does not need to be covered by operating cash flow.
Interest Coverage: INS has no debt, therefore coverage of interest payments is not a concern.
What is Instem's current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate INS's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.
High Dividend: Unable to evaluate INS's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if INS's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if INS's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of INS's dividend in 3 years as they are not forecast to pay a notable one for the UK market.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Phil Reason (57yo)
Mr. Phil J. Reason serves as the Chief Executive Officer of Instem LSS Limited, Instem Associates Limited and Instem plc (Instem Life Science Systems plc). Mr. Reason is an experienced chief executive who ...
CEO Compensation Analysis
Compensation vs Market: Phil's total compensation ($USD299.98K) is about average for companies of similar size in the UK market ($USD335.16K).
Compensation vs Earnings: Phil's compensation has been consistent with company performance over the past year.
|CEO & Executive Director||no data||UK£243.00k||4.11% £3.0m|
|CFO, Secretary & Executive Director||8.42yrs||UK£133.00k||no data|
|Chief Operating Officer||3.25yrs||no data||no data|
|Chief Scientific Officer||no data||no data||no data|
|Vice President of Global Marketing||no data||no data||no data|
|Senior Vice President of Global Sales||3.67yrs||no data||no data|
|Vice President of Corporate Development||no data||no data||no data|
|Head of People Services||1.25yrs||no data||no data|
|Executive Vice President of Regulatory eStudy Solutions||no data||no data||no data|
|Executive Vice President of Preclinical Solutions||no data||no data||no data|
Experienced Management: INS's management team is considered experienced (3.5 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
Instem plc's company bio, employee growth, exchange listings and data sources
- Name: Instem plc
- Ticker: INS
- Exchange: AIM
- Founded: 1969
- Industry: Health Care Technology
- Sector: Healthcare
- Market Cap: UK£73.365m
- Shares outstanding: 16.67m
- Website: https://www.instem.com
Number of Employees
- Instem plc
- Diamond Way
- Stone Business Park
- ST15 0SD
- United Kingdom
|Ticker||Exchange||Primary Security||Security Type||Country||Currency||Listed on|
|INS||AIM (London Stock Exchange AIM Market)||Yes||Ordinary Shares||GB||GBP||Oct 2010|
|54I||BST (Boerse-Stuttgart)||Yes||Ordinary Shares||DE||EUR||Oct 2010|
Instem plc provides information technology solutions to the life science market worldwide. The company offers solutions for data collection, management, and analysis to meet the needs of life science and healthcare organizations for data-driven decision making. Its solutions include Provantis, an integrated Windows-based system for organizations and universities that are engaged in non-clinical evaluation studies; submit platform that provides a suite of integrated tools and services for the creation and management of SEND datasets and associated documents for contract research organizations and sponsors; ALPHADAS, an eSource EDC system for early phase clinical trials; Animal Care Information System, an animal management software solution; Logbook, a repository for information; and Toxicology Resource Planning, a toxicology solution for pharmaceutical, chemical, and contract research laboratory corporations. The company also provides Comet Assay IV, a live video imaging system for reproducible comet slide scoring; and Sorcerer Colony Counter for automatic plate counter; Cyto Study Manager, a data acquisition and reporting solution; Ames Study Manager, plate countiner; Sorcerer Colony Counter for automatic plate counter; NOTOCORD-hem and NOTOCORD-fps software platforms to acquire, display, and analyze physiological signals; SEND Explorer, a Web-based application with optional data warehousing capabilities; and SRS data integration platform. It also provides data management, cloud, safety assessment, regulatory information management, solution deployment, and validation services. Additionally, it provides software solutions for extracting intelligence from research and development related healthcare data; and develops, manufactures, and supplies software and hardware products for in vitro study data collection and study management. Instem plc was founded in 1969 and is headquartered in Stone, the United Kingdom.
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2020/04/10 00:42|
|End of Day Share Price||2020/04/09 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.